Saudi Central Bank Increases Stock Position in United Therapeutics Corporation $UTHR

Saudi Central Bank lifted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 82.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,761 shares of the biotechnology company’s stock after buying an additional 1,251 shares during the period. Saudi Central Bank’s holdings in United Therapeutics were worth $1,496,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in UTHR. BlackRock Inc. purchased a new stake in United Therapeutics during the second quarter valued at about $2,868,735,000. Wellington Management Group LLP raised its holdings in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. Jupiter Topco LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at about $450,140,000. Norges Bank acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $293,418,000. Finally, Avoro Capital Advisors LLC grew its holdings in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Up 2.1%

Shares of NASDAQ:UTHR opened at $497.97 on Wednesday. United Therapeutics Corporation has a 52-week low of $392.17 and a 52-week high of $609.35. The company has a 50 day moving average of $523.93 and a two-hundred day moving average of $540.20. The company has a market capitalization of $21.36 billion, a price-to-earnings ratio of 17.82, a price-to-earnings-growth ratio of 2.43 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter last year, the firm posted $6.41 earnings per share. The business’s quarterly revenue was down 1.9% on a year-over-year basis. On average, equities analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on UTHR shares. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research report on Thursday, August 6th. JPMorgan Chase & Co. boosted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Bank of America cut their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $549.29, for a total transaction of $5,492,900.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,368,398.04. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $549.15, for a total value of $5,216,925.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,247,713.95. This represents a 19.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 384,575 shares of company stock worth $203,490,753 in the last quarter. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.